Trial Profile
Randomized Phase II, 2-arm Study of Pembrolizumab After High Dose Radiation (SBRT) Versus Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PEMBRO-RT
- 10 Apr 2021 Results (n=72) assessing immunogenomic mechanisms of response and resistance to combined radiation and immunotherapy in patients with advanced non-small cell lung cancer from PEMBRO-RT trial, presented at the 112th Annual Meeting of the American Association for Cancer Research.
- 14 Aug 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results of pooled analysis validating and exploring whether RT improves mNSCLC patient responses to immunotherapy presented at the 56th Annual Meeting of the American Society of Clinical Oncology